NASDAQ:COYA Coya Therapeutics (COYA) Stock Price, News & Analysis $4.86 +0.22 (+4.66%) Closing price 06/4/2026 03:59 PM EasternExtended Trading$4.86 0.00 (-0.02%) As of 06/4/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Coya Therapeutics Stock (NASDAQ:COYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Coya Therapeutics alerts:Sign Up Key Stats Today's Range$4.64▼$5.0150-Day Range$3.78▼$5.2652-Week Range$3.71▼$7.75Volume156,084 shsAverage Volume172,525 shsMarket Capitalization$113.92 millionP/E RatioN/ADividend YieldN/APrice Target$16.00Consensus RatingModerate Buy Company Overview Coya Therapeutics, Inc. (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments. Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors. The company employs a proprietary screening platform to identify and optimize compounds that selectively bind or inhibit UNC-45A in diseased tissues, while minimizing off-target effects in healthy cells. In addition to its internal research, Coya has established collaborations with academic and industry partners to accelerate translational studies and position its candidates for clinical entry. Headquartered in Boston, Massachusetts, Coya Therapeutics leverages a multidisciplinary team of scientists with expertise in molecular biology, medicinal chemistry and translational medicine. The company is committed to advancing its pipeline through proof‐of‐concept studies, with the goal of delivering novel therapies that improve outcomes for patients suffering from high‐unmet‐need fibrotic and oncologic indications. Coya’s strategic focus on mechanistic innovation seeks to create durable treatment options where current standards of care are limited.AI Generated. May Contain Errors. Read More Coya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreCOYA MarketRank™: Coya Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 360th out of 865 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingCoya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCoya Therapeutics has a consensus price target of $16.00, representing about 229.5% upside from its current price of $4.86.Amount of Analyst CoverageCoya Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Coya Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Coya Therapeutics are expected to decrease in the coming year, from ($1.50) to ($1.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Coya Therapeutics is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Coya Therapeutics is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCoya Therapeutics has a P/B Ratio of 2.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Coya Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.96% of the float of Coya Therapeutics has been sold short.Short Interest Ratio / Days to CoverCoya Therapeutics has a short interest ratio ("days to cover") of 4.03.Change versus previous monthShort interest in Coya Therapeutics has recently decreased by 0.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCoya Therapeutics does not currently pay a dividend.Dividend GrowthCoya Therapeutics does not have a long track record of dividend growth. News and Social Media3.1 / 5News SentimentN/A News SentimentCoya Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.Search Interest5 people have searched for COYA on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows3 people have added Coya Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Coya Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.10% of the stock of Coya Therapeutics is held by insiders.Percentage Held by Institutions39.75% of the stock of Coya Therapeutics is held by institutions.Read more about Coya Therapeutics' insider trading history. Receive COYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. COYA Stock News HeadlinesCoya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development SummitMay 28, 2026 | uk.finance.yahoo.comCoya Therapeutics secures FDA fast track status for COYA 302May 14, 2026 | finance.yahoo.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions. | Weiss Ratings (Ad)Coya Therapeutics Inc COYAMay 12, 2026 | morningstar.comMCoya Therapeutics Establishes $30 Million ATM Equity ProgramMay 12, 2026 | tipranks.comCoya Therapeutics Updates Q1 Results, COYA 302 ProgressMay 12, 2026 | tipranks.comCoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateMay 12, 2026 | businesswire.comCoya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in ...April 10, 2026 | finance.yahoo.comSee More Headlines COYA Stock Analysis - Frequently Asked Questions How have COYA shares performed this year? Coya Therapeutics' stock was trading at $5.80 at the start of the year. Since then, COYA stock has decreased by 16.3% and is now trading at $4.8560. How were Coya Therapeutics' earnings last quarter? Coya Therapeutics, Inc. (NASDAQ:COYA) issued its quarterly earnings results on Tuesday, May, 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.07. The firm earned $0.25 million during the quarter, compared to the consensus estimate of $0.15 million. Coya Therapeutics had a negative net margin of 266.10% and a negative trailing twelve-month return on equity of 55.86%. When did Coya Therapeutics IPO? Coya Therapeutics (COYA) raised $15 million in an initial public offering (IPO) on Thursday, December 29th 2022. The company issued 3,050,000 shares at a price of $5.00 per share. Who are Coya Therapeutics' major shareholders? Top institutional investors of Coya Therapeutics include Renaissance Technologies LLC (0.44%), Dimensional Fund Advisors LP (0.41%), ADAR1 Capital Management LLC (0.17%) and Cetera Investment Advisers (0.13%). Insiders that own company stock include David S Snyder, Arun Swaminathan and Fred Grossman. View institutional ownership trends. How do I buy shares of Coya Therapeutics? Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Coya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Coya Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Arista Networks (ANET), Disc Medicine (IRON), Jabil (JBL), Adobe (ADBE) and e.l.f. Beauty (ELF). Company Calendar Last Earnings5/12/2026Today6/04/2026Next Earnings (Estimated)8/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (4m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 COYA's financial health is in the Red zone, according to TradeSmith. COYA has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:COYA CIK1835022 Webwww.coyatherapeutics.com Phone800-587-8170FaxN/AEmployees6Year Founded2016Price Target and Rating Average Price Target for Coya Therapeutics$16.00 High Price Target$18.00 Low Price Target$14.00 Potential Upside/Downside+229.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.23 million Net Margins-266.10% Pretax Margin-266.07% Return on Equity-55.86% Return on Assets-48.86% Debt Debt-to-Equity RatioN/A Current Ratio15.02 Quick Ratio15.02 Sales & Book Value Annual Sales$7.95 million Price / Sales14.33 Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book2.36Miscellaneous Outstanding Shares23,460,000Free Float22,026,000Market Cap$113.92 million OptionableNot Optionable Beta0.62 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:COYA) was last updated on 6/5/2026 by MarketBeat.com Staff. From Our PartnersThe 1934 playbookIn 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Coya Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COYA Stock Alerts